Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT ID: NCT04885972

Last Updated: 2023-01-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 124 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-15
• Study Completion Date: 2023-11-30

Brief Summary

This study evaluates the efficacy and safety of a single IA injection of various RTX doses, Zilretta or placebo for the treatment of pain due to moderate to severe osteoarthritis knee pain..

Detailed Description

This study is a multi-center, Phase 2, randomized, dose ranging, assessor-blinded, active and placebo-controlled, parallel-group prospective study evaluating the efficacy and safety of a single IA injection of various RTX doses, Zilretta or placebo for the treatment of pain due to moderate to severe osteoarthritis knee pain.

A planned 112 subjects will be randomized to one of 7 groups (n=16 each) with each subject receiving one IA injection in the index knee joint (the knee primarily affected by pain if bilateral).

Conditions

Osteoarthritis, Knee; Knee Osteoarthritis; Knee Pain Chronic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Resiniferatoxin

7.5 mcg, 10 mcg, 12.5 mcg, 15 mcg, or 20 mcg in 5 mL injected once intra-articularly

Group Type: EXPERIMENTAL

Resiniferatoxin

Intervention Type: DRUG

Resiniferatoxin is a compound purified from natural sources.

Zilretta

32 mg in 5 mL injected once intra-articularly

Group Type: ACTIVE_COMPARATOR

Zilretta

Intervention Type: DRUG

Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.

Placebo

5 mL injected once intra-articularly

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Vehicle solution

Interventions

Resiniferatoxin

Resiniferatoxin is a compound purified from natural sources.

Intervention Type: DRUG

Zilretta

Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.

Intervention Type: DRUG

Placebo

Vehicle solution

Intervention Type: DRUG

Other Intervention Names

RTX; triamcinolone acetonide

Eligibility Criteria

Inclusion Criteria

• BMI < 50 kg/m
• Have moderate-to-severe pain in the index knee due to osteoarthritis (OA) as assessed by the investigator, based on American College of Rheumatology criteria
• Have had OA pain duration in the index knee ≥ 6 months prior to Screening
• Reports worst daily average pain with walking of ≥ 4 on the 0 to 10 NRS for pain intensity during the week prior to Screening
• Have a knee x-ray or MRI scan with KL grade ≥ 2 in the index knee based upon radiographic images obtained within 3 months prior to Screening (image must be available for review)
• Have had treatment failure with at least two prior analgesic agents (at least one NSAID) defined as discontinuation due to side effects or inadequate response to treatment
• Willing to abstain from other IA injections or knee surgery for at least 6 months after study treatment unless elects early discontinuation from the study
• Able to comply with the study procedures and give informed consent
• If on any analgesic medications, have been taking a stable dose for at least one month prior to screening with no increase in dose leading up to study treatment. Note that if the subject is on "as needed" or PRN analgesic medications, these may be continued during the study
• Willing to follow contraception guidelines

Exclusion Criteria

• Have a history of a hemorrhagic event that is CTCAEv5 Grade 2 or higher within the 6 months prior to screening
• Have evidence of or history of a serious coagulopathy or hemostasis problem at Screening or Baseline
• Have had an IA injection in the index knee within one month prior to screening (3 months if prior IA injection with Zilretta)
• Have undergone arthroscopic or open surgery or replacement surgery to the index knee within 6 months of screening
• Have surgical hardware or other foreign bodies within the index knee joint
• Have current instability/misalignment in the index knee post repair
• Have a sensory peripheral neuropathy that is CTCAEv5 Grade 2 or higher involving the index leg at Screening
• Have significant pain in other joints or body locations that make it difficult to assess pain in the index knee
• If on opioid analgesics to treat knee OA, have an upper limit of 30 mg/day as converted to an oral morphine equivalent dose
• Have a history of substance abuse
• Have an allergy or hypersensitivity to capsaicin, chili peppers, lidocaine or resiniferatoxin
• Pregnant at Screening or planning on becoming pregnant or currently breastfeeding
• Have had a non-study related minor surgical procedure ≤ 3 days or major surgical procedure ≤ 14 days prior to Screening and must be sufficiently recovered and stable prior to study treatment
• Have any medical condition or medical comorbidities that, in the Investigator's opinion, could adversely impact study participation or safety, conduct of the study, or interfere with pain assessments

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sorrento Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mike Royal, MD

Role: STUDY_DIRECTOR

Sorrento Therapeutics, Inc.

Locations

Horizon Clinical Research

La Mesa, California, United States

Lotus Clinical Research

Pasadena, California, United States

Affinity Health

Oak Brook, Illinois, United States

Advance Pain

Edgewood, Kentucky, United States

HD Research LLC

Bellaire, Texas, United States

HD Research LLC

Carrollton, Texas, United States

Countries

United States

Other Identifiers

RTX-OAK-201

Identifier Type: -

Identifier Source: org_study_id